Aclaris Therapeutics, Inc. Cash Flow Statement
ACRS|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Aclaris Therapeutics, Inc. used $47M in operating cash flow and negative free cash flow of $47M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$64.9M | -$88.5M | -$90.9M | -$86.9M | -$90.9M | -$132.7M | -$68.5M | -$132.7M | -$20.6M |
| Depreciation & Amortization | $454.0K | $863.0K | $923.0K | $797.0K | $923.0K | $1.9M | $402.0K | $1.9M | $90.0K |
| Operating Cash Flow | -$47.1M | -$78.3M | -$52.1M | -$67.6M | -$52.1M | -$100.8M | -$54.7M | -$100.8M | -$20.4M |
| Capital Expenditures | $111.0K | $1.3M | $308.0K | $605.0K | $308.0K | $1.4M | $1.2M | $1.4M | $507.0K |
| Free Cash Flow | -$47.2M | -$79.6M | -$52.4M | -$68.2M | -$52.4M | -$102.2M | -$55.9M | -$102.2M | -$20.9M |
| FCF Margin | -603.4% | -254.8% | -775.6% | -229.1% | -775.6% | -1661.0% | -3321.3% | -1661.0% | -1240.4% |